AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9277640 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 600‐kcal breakfast at 8 AM (phase A)
Number of subjects: 20
Study 9277640 — intervention group
Group type: COMPARATOR
Intervention: Prolonged fasting (phase B)
Number of subjects: 20
Study 8436090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (CLO) 25 ml daily for 8 weeks
Number of subjects: 34
Study 3946922 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol 0.5%
Number of subjects: 24
Study 3946922 — intervention group
Group type: COMPARATOR
Intervention: Topical betaxolol 1%
Number of subjects: 24
Study 30954948 — intervention group
Group type: EXPERIMENTAL
Intervention: Online injury prevention programme; participants received access to information on evidence-based risk factors and advice to reduce injury risk.
Number of subjects: 2378
Study 30954948 — intervention group
Group type: COMPARATOR
Intervention: Control group; participants followed their regular preparation for the running event.
Number of subjects: 2378
Study 30954948 — intervention group
Group type: EXPERIMENTAL
Intervention: Online injury prevention programme; specifically for runners with no injuries in the 12 months preceding the trial.
Number of subjects: 2378
Study 29649927 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced practice with different environmental context scenes
Number of subjects: 0
Study 29649927 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced practice with the same environmental context scene
Number of subjects: 0
Study 29649927 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed practice with different environmental context scenes
Number of subjects: 0
Study 29649927 — intervention group
Group type: COMPARATOR
Intervention: Massed practice with the same environmental context scene
Number of subjects: 0
Study 26739253 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic lifestyle intervention (CHIP Germany), 40-hour coaching program
Number of subjects: 83
Study 26739253 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 23588342 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour outpatient methotrexate infusion
Number of subjects: 161
Study 23588342 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour inpatient methotrexate infusion
Number of subjects: 161
Study 23588342 — intervention group
Group type: COMPARATOR
Intervention: Healthy control populations
Number of subjects: 161
Study 22172966 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 3 weeks
Number of subjects: 71
Study 22172966 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 3 weeks
Number of subjects: 71
Study 20815898 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nCPAP
Number of subjects: 35
Study 20815898 — intervention group
Group type: COMPARATOR
Intervention: Sham nCPAP
Number of subjects: 35
Study 17140611 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological awareness and grapheme-to-phoneme conversion training
Number of subjects: 10
Study 17140611 — intervention group
Group type: COMPARATOR
Intervention: Non-auditory training (Control)
Number of subjects: 10
Study 15761456 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression
Number of subjects: 90
Study 15761456 — intervention group
Group type: COMPARATOR
Intervention: Mechanical compression with the Compressar
Number of subjects: 90
Study 15761456 — intervention group
Group type: COMPARATOR
Intervention: Mechanical compression with the Femostop
Number of subjects: 90
Study 14702863 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention provided by nurses
Number of subjects: 0
Study 10195630 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoclaved vaccine
Number of subjects: 68
Study 10195630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonautoclaved vaccine
Number of subjects: 68
Study 10195630 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 8892450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (total dose 100-185 mg/m²)
Number of subjects: 132
Study 8892450 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (dose ranged from 59.5 to 76.5 Gy)
Number of subjects: 132
Study 8892450 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups (under 30, 30-50, over 50)
Number of subjects: 132
Study 8892450 — intervention group
Group type: EXPERIMENTAL
Intervention: Postirradiation serous otitis media (SOM)
Number of subjects: 132
Study 8892450 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and radiation dose or fractionation
Number of subjects: 132
Study 8892450 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 132
Study 1734985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin treatment and home blood glucose monitoring
Number of subjects: 0
Study 1734985 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 0
Study 6465581 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg) with sodium citrate
Number of subjects: 60
Study 6465581 — intervention group
Group type: COMPARATOR
Intervention: Meperidine alone
Number of subjects: 60
Study 6465581 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine plus metoclopramide (20 mg)
Number of subjects: 60
Study 6465581 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam plus metoclopramide (20 mg)
Number of subjects: 60
Study 6465581 — intervention group
Group type: COMPARATOR
Intervention: Control group (meperidine or diazepam without metoclopramide)
Number of subjects: 60
Study 2429084 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg once daily)
Number of subjects: 17
Study 2429084 — intervention group
Group type: COMPARATOR
Intervention: ICI 118,551 (20 mg t.i.d.)
Number of subjects: 17
Study 2429084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 29656373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 0
Study 29656373 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 0
Study 29656373 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID3 remission/LDA
Number of subjects: 0
Study 28185792 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus Cisplatin (Doc-Cis)
Number of subjects: 148
Study 28185792 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed plus Cisplatin (Pem-Cis)
Number of subjects: 148
Study 25731897 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (40 mg/kg) and nebulized epinephrine (0.1 ml/kg)
Number of subjects: 120
Study 25731897 — intervention group
Group type: COMPARATOR
Intervention: Nebulized epinephrine (0.1 ml/kg)
Number of subjects: 120
Study 24085591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 544
Study 24085591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 544
Study 24085591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 21422467 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 100
Study 21422467 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 100
Study 18326596 — intervention group
Group type: EXPERIMENTAL
Intervention: High rTFA diet (10.2 g/2500 kcal)
Number of subjects: 38
Study 18326596 — intervention group
Group type: EXPERIMENTAL
Intervention: iTFA diet (10.2 g/2500 kcal)
Number of subjects: 38
Study 18326596 — intervention group
Group type: COMPARATOR
Intervention: Moderate rTFA diet (4.2 g/2500 kcal)
Number of subjects: 38
Study 16436342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadifloxacin 1% cream
Number of subjects: 474
Study 16436342 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 2% cream
Number of subjects: 474
Study 14628252 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (1, 3, and 10 ng/kg/min for 45 min)
Number of subjects: 9
Study 14628252 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 9
Study 14628252 — intervention group
Group type: COMPARATOR
Intervention: AT (1)-receptor antagonist (160 mg valsartan) prior to angiotensin II infusion
Number of subjects: 9
Study 14628252 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion and AT (1)-antagonist administration
Number of subjects: 9
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1105
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1105
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1105
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1105
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1105
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 1105
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (by race)
Number of subjects: 1105
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (by race)
Number of subjects: 1105
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (by race)
Number of subjects: 1105
Study 10737282 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (by race-region)
Number of subjects: 1105
Study 8731547 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment for PTSD
Number of subjects: 24
Study 8731547 — intervention group
Group type: COMPARATOR
Intervention: Treatment/wait list comparison group (weekly PTSD outpatient group therapy)
Number of subjects: 24
Study 1576620 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (I-C)
Number of subjects: 352
Study 1576620 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin+aminoglycoside (C+A)
Number of subjects: 352
Study 3902602 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg orally once daily
Number of subjects: 10
Study 3902602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31790425 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention for cannabis use
Number of subjects: 262
Study 29744866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling and twice‐weekly exercise classes
Number of subjects: 606
Study 29744866 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity level (≥16 metabolic equivalent of task‐hours moderate‐to‐vigorous physical activity/week)
Number of subjects: 606
Study 26474192 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX (Group 2)
Number of subjects: 261
Study 26474192 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX (Group 3)
Number of subjects: 261
Study 26474192 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX (Group 1)
Number of subjects: 261
Study 26474192 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab + MTX (Groups 2 and 3 combined)
Number of subjects: 261
Study 24561570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-lesion (IL) abciximab
Number of subjects: 452
Study 24561570 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA)
Number of subjects: 452
Study 24561570 — intervention group
Group type: EXPERIMENTAL
Intervention: TA with IL abciximab
Number of subjects: 452
Study 24561570 — intervention group
Group type: COMPARATOR
Intervention: No abciximab
Number of subjects: 452
Study 24561570 — intervention group
Group type: COMPARATOR
Intervention: No TA
Number of subjects: 452
Study 22506607 — intervention group
Group type: EXPERIMENTAL
Intervention: 38-mm standard transducer
Number of subjects: 0
Study 22506607 — intervention group
Group type: COMPARATOR
Intervention: 25-mm hockey stick transducer
Number of subjects: 0
Study 21223649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure treatment group (custom pressure garment with 10% strain rate of pressure + 9 mm thick local pressure padding, worn more than 23 hours per day)
Number of subjects: 45
Study 21223649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure treatment group (5.6 mm Hg pressure)
Number of subjects: 45
Study 21223649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure treatment group (2.8 and 5.6 mm Hg pressure)
Number of subjects: 45
Study 21223649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure treatment group (various pressure levels)
Number of subjects: 45
Study 21223649 — intervention group
Group type: EXPERIMENTAL
Intervention: SPMS (smart pressure monitored suit)
Number of subjects: 45
Study 21223649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 45
Study 18722970 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Radical Hysterectomy (TLRH) / Total Robotic Radical Hysterectomy (TRRH)
Number of subjects: 740
Study 18722970 — intervention group
Group type: COMPARATOR
Intervention: Total Abdominal Radical Hysterectomy (TARH)
Number of subjects: 740
Study 16052760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian Self Priming Etchant + One Step Plus (TY)
Number of subjects: 30
Study 16052760 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 30
Study 16052760 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus Self‐Etch Primer + Optibond Solo Plus (SO)
Number of subjects: 30
Study 16052760 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid (0.5 ml)
Number of subjects: 30
Study 16052760 — intervention group
Group type: COMPARATOR
Intervention: Etch-and-rinse adhesive systems
Number of subjects: 30
Study 16052760 — intervention group
Group type: COMPARATOR
Intervention: Single Bond (SB)
Number of subjects: 30
Study 16052760 — intervention group
Group type: COMPARATOR
Intervention: ScotchBond Multi‐Purpose Plus (SC)
Number of subjects: 30
Study 14662569 — intervention group
Group type: EXPERIMENTAL
Intervention: Docusate sodium
Number of subjects: 92
Study 14662569 — intervention group
Group type: EXPERIMENTAL
Intervention: Triethanolamine polypeptide
Number of subjects: 92
Study 14662569 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 92
Study 10199756 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog plus human PTH-(1-34) (40 microg/day, s.c.)
Number of subjects: 38
Study 10199756 — intervention group
Group type: COMPARATOR
Intervention: GnRH analog alone (nafarelin acetate; 200 microg, intranasally, twice daily)
Number of subjects: 38
Study 8849298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole (Funazol)
Number of subjects: 1
Study 8849298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical itraconazole
Number of subjects: 1
Study 8849298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole (Sporanox)
Number of subjects: 1
Study 2236467 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of fluphenazine decanoate
Number of subjects: 39
Study 2236467 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine plasma levels
Number of subjects: 39
Study 484261 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for 8 days
Number of subjects: 252
Study 484261 — intervention group
Group type: COMPARATOR
Intervention: Treatment for 15 days
Number of subjects: 252
Study 30759228 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV)
Number of subjects: 415
Study 30759228 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent live‐attenuated influenza vaccine (LAIV)
Number of subjects: 415
Study 30759228 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV
Number of subjects: 415
Study 30759228 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 415
Study 31741066 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-filling mesh container (BFMC)
Number of subjects: 40
Study 31741066 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 40
Study 29884405 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal transplantation of up to 200,000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks
Number of subjects: 12
Study 27385151 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 23
Study 27385151 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized saline
Number of subjects: 23
Study 27385151 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast
Number of subjects: 23
Study 27385151 — intervention group
Group type: COMPARATOR
Intervention: Carbon dioxide
Number of subjects: 23
Study 24921418 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally oriented treatment modality
Number of subjects: 391
Study 24921418 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight oriented treatment modality
Number of subjects: 391
Study 24921418 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy
Number of subjects: 391
Study 24921418 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 391
Study 24921418 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet therapy
Number of subjects: 391
Study 24921418 — intervention group
Group type: COMPARATOR
Intervention: Orthodox Jews
Number of subjects: 391
Study 24921418 — intervention group
Group type: COMPARATOR
Intervention: Non-Orthodox Jews
Number of subjects: 391
Study 21628603 — intervention group
Group type: COMPARATOR
Intervention: Aclidinium IV doses (25-400 µg)
Number of subjects: 24
Study 21628603 — intervention group
Group type: COMPARATOR
Intervention: Inhaled aclidinium (200 µg)
Number of subjects: 24
Study 21628603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18817967 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinyl matrix
Number of subjects: 5
Study 18817967 — intervention group
Group type: EXPERIMENTAL
Intervention: Putty matrix
Number of subjects: 5
Study 18817967 — intervention group
Group type: COMPARATOR
Intervention: Putty matrix pre-cooled at 4 degrees C
Number of subjects: 5
Study 18817967 — intervention group
Group type: COMPARATOR
Intervention: Putty matrix pre-cooled in freezer
Number of subjects: 5
Study 17452937 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic device for continuous regulation of tracheal tube cuff pressure (n = 73)
Number of subjects: 142
Study 17452937 — intervention group
Group type: COMPARATOR
Intervention: Routine care of the cuff pressure (control group, n = 69)
Number of subjects: 142
Study 15370401 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin sodium suspension 2%
Number of subjects: 45
Study 15370401 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical phenytoin sodium suspension 4%
Number of subjects: 45
Study 15370401 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 45
Study 11641743 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermally stressed olive oil (TSOL)
Number of subjects: 14
Study 11641743 — intervention group
Group type: COMPARATOR
Intervention: Thermally stressed safflower oil (TSAF)
Number of subjects: 14
Study 9684780 — intervention group
Group type: EXPERIMENTAL
Intervention: YM 337
Number of subjects: 0
Study 9684780 — intervention group
Group type: COMPARATOR
Intervention: ReoPro (Control)
Number of subjects: 0
Study 7850531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic parenteral nutrition (1.44 U/kg/day regular human insulin)
Number of subjects: 11
Study 7850531 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 11
Study 3060308 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpastes containing sodium monofluorophosphate (SMFP) at fluoride levels of 1000, 1500, and 2500 ppm F
Number of subjects: 3000
Study 3060308 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpastes incorporating zinc citrate
Number of subjects: 3000
Study 3060308 — intervention group
Group type: COMPARATOR
Intervention: Zinc-free pastes
Number of subjects: 3000
Study 31514201 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 50
Study 31514201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29294501 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate (17-OHPC) 250 mg
Number of subjects: 708
Study 25897707 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 20
Study 25897707 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based education
Number of subjects: 20
Study 25897707 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 20
Study 24708775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/day
Number of subjects: 10
Study 24708775 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 10
Study 23125943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN (5 mg/24 hours)
Number of subjects: 41
Study 23125943 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing daily for 7 days
Number of subjects: 41
Study 20021250 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bevacizumab (5 mg/ml) twice a day and betamethasone four times daily for 1 week
Number of subjects: 54
Study 20021250 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone alone four times daily for 1 week
Number of subjects: 54
Study 17088311 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 0
Study 17088311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 0
Study 17088311 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16048482 — intervention group
Group type: EXPERIMENTAL
Intervention: Helixone membrane
Number of subjects: 10
Study 16048482 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69ST membrane
Number of subjects: 10
Study 12145073 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 44
Study 12145073 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 44
Study 8907343 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (10 mg/kg/day during the first week and 15 mg/kg/day thereafter)
Number of subjects: 17
Study 8907343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17